ライフサイエンスコーパス: serogroup

1 anifestation and less on meningococcal CC or serogroup.

2 ent of septic shock was not related to CC or serogroup.

3 001) and not affected by comorbidity, CC, or serogroup.

4 pneumococcal disease changes by serotype and serogroup.

5 ), a naturally attenuated member of the TBEV serogroup.

6 ction with Vibrio cholerae of the O1 or O139 serogroup.

7 in survivors was comparable between the two serogroups.

8 train genotypes among vaccine and nonvaccine serogroups.

9 more resistant to human LL-37 than other GAS serogroups.

10 ted on plasmids found across diverse E. coli serogroups.

11 lassification into different orthobunyavirus serogroups.

12 te vaccine and 8 additional key serotypes or serogroups.

13 The assay will be expanded to 40 serotypes/serogroups.

14 nd are limited in their detection of various serogroups.

15 ngitidis reference genome sequences of known serogroups.

16 ns, with the prevalence varying widely among serogroups.

17 -helices was substantially different between serogroups.

18 rogroup 1, but not other clinically relevant serogroups.

19 ogroup (67%) and included a diverse array of serogroups.

20 caused by Vibrio cholerae of the O1 or O139 serogroups.

21 ing units/ml) for both toxigenic V. cholerae serogroups.

22 trains 6077, 6206 (serogroup O11), and PA14 (serogroup 010) were less sensitive to NET capture.

23 SBT) analysis of all incoming L. pneumophila serogroup 1 (Lp1) isolates to identify potential links b

24 nd 2013 L. pneumophila patient isolates were serogroup 1 and closely related to all 2013 hospital wat

25 ella pneumophila, and Legionella pneumophila serogroup 1 in primary specimens.

26 the genus Legionella; Legionella pneumophila serogroup 1 is the causative agent of most cases in Euro

27 L. pneumophila serogroup 1 isolates (n = 106) from the standard "typing

28 Legionella pneumophila serogroup 1 isolates were cultured from patient sputum (

29 genome sequences that have been reported for serogroup 1 strains.

30 e sufficient for the detection of Legionella serogroup 1, but not other clinically relevant serogroup

31 ts there was implication of a second strain, serogroup 1.

32 f L. pneumophila from a serogroup other than serogroup 1.

33 alyses of 43 strains, including all known Lp serogroups 1-17 and 17 emergent LD-causing Legionella sp

34 L. pneumonphila (LP) serogroup-1 (Lp1) is the major cause of Legionnaires' Di

35 tive structural studies of S. pneumoniae CPS serogroup 10 (CPS10) were extended to include geneticall

36 Serogroup 11 has six members (11A to -E) and the CPS str

37 of the human pathogen Legionella pneumophila serogroup 12 strain 570-CO-H (ATCC 43290), a clinical is

38 sh Streptococcus pneumoniae serotypes within serogroup 18 from culturable/nonculturable pneumococcal

39 s fell into a single lineage associated with serogroup 23, which had an origin in 1908 as dated by co

40 B2.1 phylogenetic subgroup (56%) and O1 serogroup (27.7%) were the most frequently identified.

41 Legionella pneumophila serogroup 3 was recovered in neonatal biological samples

42 es (91%) were contaminated by L. pneumophila serogroups 3 and 10.

43 ed a diverse data set of approximately 1,000 serogroup 6 genomes, assessed the prevalence and distrib

44 Serogroup 6 has four known members (6A-6D) with distinct

45 Two atypical serogroup 6 isolates (named 6X11 and 6X12) have been dis

46 Genetic studies of serogroup 6 isolates ofStreptococcus pneumoniaeidentifie

47 Within the serotypes, serogroup 6 pneumococci are a frequent cause of serious

48 ype 6E, analyzed the genetic diversity among serogroup 6 pneumococci, and investigated whether pneumo

49 of protection against Neisseria meningitidis serogroup A (NmA) in Burkina Faso before the introductio

50 32 serogroup A carriers were identified in 4278 age-stratif

51 belt of sub-Saharan Africa, a meningococcal serogroup A conjugate vaccine (MACV) has been progressiv

52 e capsular polysaccharide (CPS), which in Nm serogroup A consists of N-acetyl-mannosamine-1-phosphate

53 To combat Neisseria meningitidis serogroup A epidemics in the meningitis belt of sub-Saha

54 -TT vaccine could end epidemic meningitis of serogroup A in sub-Saharan Africa.

55 PSA-TT was highly effective at prevention of serogroup A invasive meningococcal disease and carriage

56 s were conducted after introduction of a new serogroup A meningococcal conjugate vaccine (MenAfriVac)

57 e, highly immunogenic Neisseria meningitidis serogroup A meningococcal conjugate vaccine (PsA-TT) was

58 cal meningitis and carriage in Chad during a serogroup A meningococcal meningitis epidemic.

59 No cases of serogroup A meningococcal meningitis occurred among vacc

60 Despite enhanced surveillance, no case of serogroup A meningococcal meningitis was reported in the

61 A serogroup A meningococcal polysaccharide-tetanus toxoid

62 months before vaccination, whereas only one serogroup A meningococcus was isolated in 5001 people li

63 The incidence of laboratory-confirmed serogroup A N meningitidis dropped significantly to 0.01

64 provide population-level protection against serogroup A Neisseria meningitidis (MenA) are unknown.

65 The conjugate vaccine against serogroup A Neisseria meningitidis (NmA), MenAfriVac, wa

66 critical for the replication and assembly of serogroup A rotavirus (RVA); however, the dramatic prima

67 accinated with meningococcal serogroup B and serogroup A, C, W, Y vaccines.

68 s one such lineage of meningococci, known as serogroup A, clonal complex 5 (A:cc5), has caused three

69 oduction of a glycoconjugate vaccine against serogroup A.

70 ular polymerases from Neisseria meningitidis serogroups A (CsaB) and X (CsxA) were characterized.

71 Neisseria meningitidis serogroups A and X are among the leading causes of bacte

72 polyhexosamine phosphates in N. meningitidis serogroups A and X.

73 SP4 has maintained viroporin activity across serogroups A to C.

74 c genes in the cap locus for N. meningitidis serogroups A, B, C, W135, X, and Y.

75 Meningococcal conjugate vaccines against serogroups A, C, W, and Y (MenACWY) are recommended for

76 ived from hydrolysis of mixtures of the four serogroups A, C, W, and Y reference polysaccharides.

77 vaccines are available against meningococcal serogroups A, C, W, and Y.

78 The meningococcal serogroups A, W, and X have been responsible for epidemi

79 oniae lytA (NHS assay); (ii) N. meningitidis serogroups A, W135, and X (AWX assay); and (iii) N. meni

80 Serogroup and MIC to penicillin, rifampin and chloramphe

81 servations highlight the difficulties in the serogrouping and capsular genogrouping of meningococcal

82 ant against threats from other meningococcal serogroups and other pathogens.

83 animal pathogens classified within multiple serogroups and species.

84 of age, comorbidity, clinical manifestation, serogroup, and CC on disease course and outcome was asse

85 In Sweden, serogroup Y is now the dominating serogroup, and in 2012, the serogroup Y disease incidenc

86 ecific for detecting its target organisms or serogroups, and the LLD was similar to that for the sing

87 strains belonging to the hypervirulent M1T1 serogroup are more resistant to human LL-37 than other G

88 The capsule polymerases (CPs) of these serogroups are members of the Stealth protein family com

89 d vaccine-related serotypes (ie, in the same serogroup as a vaccine serotype).

90 to uncover the genomic basis of conflicting serogroup assay results for an isolate (M16917) from a p

91 f the randomly selected STEC belonged to key serogroups associated with human disease and none encode

92 quadrivalent glycoconjugate (MenACWY-CRM) or serogroup B (4CMenB) vaccination on meningococcal carria

93 ecember 2013, a multicomponent meningococcal serogroup B (4CMenB) vaccine was used before licensure o

94 Neisseria meningitidis serogroup B (MnB) is a leading cause of bacterial mening

95 nsed vaccines against Neisseria meningitidis serogroup B (NmB) will depend partly on disease burden e

96 er milliliter (90 596 and 114 683 CFU/mL for serogroup B and C strains, respectively; P < .0001 compa

97 healthy adults vaccinated with meningococcal serogroup B and serogroup A, C, W, Y vaccines.

98 ed any meningococcal bacteria and 4% carried serogroup B by rt-PCR.

99 dly reduce meningococcal carriage or prevent serogroup B carriage acquisition.

100 Total meningococcal and genotypically serogroup B carriage prevalence among sampled students w

101 nB-4C was associated with decreased total or serogroup B carriage prevalence.

102 Ten students acquired serogroup B carriage: 3 after 1 MenB-FHbp dose, 4 after

103 010, we investigated a prolonged outbreak of serogroup B disease associated with a university.

104 d in the USA for prevention of meningococcal serogroup B disease in 10-25-year-olds.

105 se-control study to examine risk factors for serogroup B disease.

106 es developed for prevention of meningococcal serogroup B disease.

107 vasive meningococcal disease cases caused by serogroup B has increased.

108 disease in developed countries is caused by serogroup B infection, against which there is no univers

109 Immunization registry data and serogroup B invasive meningococcal disease (B-IMD) cases

110 MenB-FHbp (factor H binding protein), a serogroup B meningococcal (MenB) vaccine, was used to co

111 Limited data exist on the impact of the serogroup B meningococcal (MenB) vaccines MenB-FHbp and

112 identified in 87 (36%) of 244 children with serogroup B meningococcal disease and 49 (15%) of 328 co

113 age was 6.5 (SD 2.8) years in children with serogroup B meningococcal disease and 6.9 (2.9) in contr

114 umatic stress disorder between children with serogroup B meningococcal disease and controls.

115 gainst additional pneumococcal serotypes and serogroup B meningococcal disease are important.

116 Serogroup B meningococcal disease caused 7 US university

117 noted in three (1%) of 239 children who had serogroup B meningococcal disease compared with none of

118 Eligible children were survivors who had had serogroup B meningococcal disease confirmed by culture o

119 ines, public health response to outbreaks of serogroup B meningococcal disease is limited by lack of

120 Serogroup B meningococcal disease is the commonest cause

121 ination campaign in response to a university serogroup B meningococcal disease outbreak in 2015.

122 w vaccines and suggest that all survivors of serogroup B meningococcal disease should be screened for

123 In the full sample, children who had serogroup B meningococcal disease were more likely than

124 Most children survive serogroup B meningococcal disease without major sequelae

125 uced 4CMenB-a multicomponent vaccine against serogroup B meningococcal disease-into the national infa

126 e disease burden in children having survived serogroup B meningococcal disease.

127 in-based vaccine licensed to protect against serogroup B meningococcal disease.

128 Invasive serogroup B meningococcal isolates from cases in England

129 Researchers were masked to the children's serogroup B meningococcal status.

130 Assessment of new serogroup B meningococcal vaccines is hampered by a scar

131 duce mortality and morbidity associated with serogroup B meningococci infections, but uncertainty rem

132 tralia, meningitis and septicaemia caused by serogroup B meningococci remain uncontrolled.

133 the vaccine might induce against the diverse serogroup B meningococci strains that cause disease.

134 ra from individuals colonized long term with serogroup B meningococci were also upregulated during pr

135 revention of sepsis and meningitis caused by serogroup B meningococci.

136 nt of two recently licensed vaccines against serogroup B meningococcus (MenB).

137 In this study, the transcriptome of adherent serogroup B N. meningitidis strain MC58 was determined a

138 Serogroup B Neisseria meningitidis (MenB) is a major cau

139 Among 25 serogroup B Neisseria meningitidis clinical isolates, we

140 tly no commercial vaccine to protect against serogroup B or against N. gonorrhoeae.

141 hogens isolated, 102 (76.1%) were Salmonella serogroup B or D.

142 to the introduction of an approximately 2-kb serogroup B sequence cassette into the serogroup C genom

143 uebec, starting in 2003, and was caused by a serogroup B sequence type 269 clone.

144 The outbreak was associated with a novel serogroup B strain (CC269) and risk factors were indicat

145 512) strains, thereby providing at least 82% serogroup B strain coverage.

146 Bexsero and Trumenba, against meningococcal serogroup B strains have been licensed; both vaccines co

147 there is no currently available vaccine for serogroup B strains of N. meningitidis, this kind capsul

148 meningitidis species, with high sensitivity (serogroup B synD, 99% [75/76]; W135 synG, 97% [38/39]; a

149 (LLD) were 9, 43, and 10 copies/reaction for serogroup B synD, W135 synG, and Y synF assays, respecti

150 New singleplex real-time PCR assays for serogroup B synD, W135 synG, and Y synF showed 100% spec

151 mplement (hSBA) by use of four meningococcal serogroup B test strains expressing vaccine-heterologous

152 participants for three of four meningococcal serogroup B test strains representative of disease-causi

153 participants for three of four meningococcal serogroup B test strains representative of disease-causi

154 Understanding serogroup B transmission in college and other settings w

155 The multicomponent meningococcal serogroup B vaccine (4CMenB) is an outer membrane vesicl

156 immunized rhesus macaques with a 4-component serogroup B vaccine (4CMenB).

157 nsider the implementation of a meningococcal serogroup B vaccine for young children and/or serogroup

158 MenB-4C is a recently licensed meningococcal serogroup B vaccine.

159 ble herd immunity effects with meningococcal serogroup B vaccines and the need for a booster dose to

160 e and other settings will help inform use of serogroup B vaccines currently under consideration for l

161 ease seen in the Southern cone was caused by serogroup B, but serogroup W135 strains have increased i

162 steria monocytogenes, Neisseria meningitidis serogroup B, Candida albicans, and P. berghei ANKA, and

163 Ten cases were determined to be serogroup B.

164 polymerase gene (synD) of M16917 belongs to serogroup B.

165 xico, Central America and Caribbean regions, serogroups B and C were equally present, and serogroup Y

166 and X (AWX assay); and (iii) N. meningitidis serogroups B, C, and Y (BCY assay).

167 However, the assay sensitivity for serogroups B, W135, and Y is low.

168 Vaccination with meningococcal serogroup C (MenC) conjugate (MCC) polysaccharide vaccin

169 am-negative Neisseria meningitidis, capsular serogroup C (MenC) or Gram-positive group B Streptococcu

170 intact, heat-killed Neisseria meningitidis, serogroup C (MenC), a gram-negative bacterium.

171 71.5%) that were positive for N meningitidis serogroup C (NmC).

172 increase in the incidence of serogroup W and serogroup C between both countries.

173 of isolates from clonal complexes with high serogroup C capsule expression rate during carriage (seq

174 of cssA/B/C and a part of csc, encoding the serogroup C capsule polymerase.

175 5 all provinces introduced the meningococcal serogroup C conjugate vaccine (MCCV) into their routine

176 Following vaccine introduction, serogroup C disease decreased to <0.05 per 100 000 per y

177 lance data for meningococcal serogroup W and serogroup C disease in the Netherlands and England for t

178 Prior to MCCV introduction, serogroup C disease incidence was 0.07-0.25 per 100 000

179 meningococcal serogroup W with meningococcal serogroup C emergence, the rapid expansion of the MenW:c

180 2-kb serogroup B sequence cassette into the serogroup C genomic background.

181 MCCV dramatically reduced the incidence of serogroup C IMD in Canada through both direct and indire

182 ells were measured before a booster of a Hib-serogroup C meningococcal (MenC) conjugate vaccine and a

183 We measured the frequency of circulating serogroup C meningococcal (MenC)-specific memory B cells

184 Several clusters of serogroup C meningococcal disease among men who have sex

185 Although serogroup C meningococcal disease has all but disappeare

186 ases caused by clonal complex ST-11 and ST-8 serogroup C meningococci decreased from 251 of 268 (94%)

187 erogroup B vaccine for young children and/or serogroup C or ACWY conjugate vaccine for adolescents.

188 00 000 per year, with 40% of cases caused by serogroup C organisms.

189 rent serogroup W outbreak and the historical serogroup C outbreak, the increase in incidence started

190 Netherlands and England, and the historical serogroup C outbreaks in both countries.

191 ic BMEM induced in humans by a meningococcal serogroup C PS (Men C)-TT conjugate vaccine conform to t

192 isolates from cluster-associated cases were serogroup C sequence type 11.

193 admissions decreased after the meningococcal serogroup C vaccine was introduced in 1999 and was 12.40

194 Serogroup C was the main cause of disease in Brazil; the

195 e group, which is most often associated with serogroup C.

196 Determination of sialic acid serogroups (C, W-135, and Y) unambiguously is complex si

197 hypertension, coronary arterial disease, and serogroup C1 infections-were each assigned +1 point to f

198 e scheme, 39 pairs of serovars in Salmonella serogroup C2 differ only by the minor antigen O:6(1).

199 rom 10 serovars representing five Salmonella serogroup C2 pairs.

200 disease (IMD) isolates, which can be readily serogrouped, carriage isolates often lack capsule expres

201 rimean-Congo hemorrhagic fever virus (CCHFV) serogroup comprises sole members CCHFV and Hazara virus

202 Y) unambiguously is complex since all these serogroups contribute to the sialic acid monosaccharide

203 uence-specific PCRs to identify 74 serotypes/serogroups covering all current vaccine types as well as

204 and 36.2% (15.6-51.7) carriage reduction for serogroup CWY.

205 Y (29.6% [8.1-46.0] carriage reduction), and serogroups CWY (28.5% [2.8-47.5] carriage reduction) com

206 ns and phylogenetic analysis showed that the serogroup diagnostic capsule polymerase gene (synD) of M

207 There was a significant change (P < .05) in serogroup distribution among all age groups between the

208 Core surveillance (ABCs) were characterized; serogroup distribution and molecular features of these i

209 Serogroup distribution was highly variable among countri

210 e to horizontal gene transfer and changes in serogroup distribution.

211 lates was retained for all serogroups except serogroup E which has a synthetic requirement for UDP-Ga

212 meningococcal isolates was retained for all serogroups except serogroup E which has a synthetic requ

213 the phenotypic methods correctly identified serogroups for 69 to 98% of IMD isolates.

214 onsible for the increased prevalence of this serogroup in Sweden.

215 adapted for the monitoring of L. pneumophila serogroups in clinical and environmental samples in a fe

216 adapted for the monitoring of all Legionella serogroups in clinical and environmental samples.

217 Vibrio cholerae belonging to the O1 and O139 serogroups is commonly associated with epidemic diarrhea

218 ethods were evaluated for their abilities to serogroup isolates and were compared with two genotyping

219 melon silver mottle virus (WSMoV, tospovirus serogroup IV) and melon yellow spot virus (MYSV, tospovi

220 melon silver mottle virus (WSMoV, tospovirus serogroup IV), and Melon yellow spot virus (MYSV, tospov

221 Because the N. meningitidis serogroup L capsule polymer consists of a trimeric repea

222 esis of the complex trimeric N. meningitidis serogroup L capsule polymer repeating unit.

223 hysiologically less relevant N. meningitidis serogroup L, is one of the smallest known Stealth protei

224 %) were identified correctly at least to the serogroup level, including all of the 13-valent conjugat

225 sms, including expression of capsule (select serogroups), Neisserial surface protein A (NspA), factor

226 cing of a multilocus sequence type 95 (ST95) serogroup O1 strain previously indicated that APEC resem

227 the classical and El Tor biotype strains of serogroup O1 that is most frequently associated with epi

228 525 stool specimens, and all organisms were serogroup O1.

229 rrhoeal disease caused by certain strains of serogroup O1/O139 Vibrio cholerae.

230 h the detection of toxigenic Vibrio cholerae serogroups O1 and O139, which are associated with choler

231 disease caused by Vibrio cholerae strains of serogroups O1 and O139.

232 cytotoxic P. aeruginosa strains 6077, 6206 (serogroup O11), and PA14 (serogroup 010) were less sensi

233 higa toxin-producing Escherichia coli (STEC) serogroup O121 and O26 infections linked to contaminated

234 detection for seven STEC strains of various serogroups (O26, O45, O103, O111, O121, O145, and O157)

235 V. parahaemolyticus RIMD2210633, a clinical serogroup O3:K6 isolate, and examined the effects in viv

236 ile the invasive P. aeruginosa strains PAO1 (serogroup O5) and 6294 (serogroup O6) were trapped by NE

237 in intestinal colonization of cattle by EHEC serogroup O5, O111, and O26 strains.

238 ginosa strains PAO1 (serogroup O5) and 6294 (serogroup O6) were trapped by NETs, the cytotoxic P. aer

239 genic E. coli (ETEC) strain of the same ST23 serogroup O78 lineage.

240 rains of another dominant APEC lineage (ST23 serogroup O78 strains chi7122 and IMT2125) and compared

241 Serotyping and serogrouping of Salmonella isolates was performed using

242 ing the smpB gene was designed to detect all serogroups of H. influenzae.

243 demonstrated for the analysis of 9 different serogroups of the bacterium Legionella pneumophila, a co

244 f a genome sequence of L. pneumophila from a serogroup other than serogroup 1.

245 trains (P = .014) and severe disease with O7 serogroup (P = .034) and PapGII adhesin (OR, 2.3 [95% CI

246 ction using multivariable analysis were D+R- serogroup (P</=0.0001), donor age >50 years (P=0.013), a

247 nation of the different ExPEC subpathotypes, serogroups, phylogenetic types, and sequence types.

248 Unlike that for serogroups prevented by quadrivalent meningococcal vacci

249 primary sequence divergence of NSP4s across serogroups raises the possibility that viroporin activit

250 Vaccine-induced serogroup replacement was not observed, although a small

251 entify 11 individual serotypes plus 10 small serogroups representing the majority of disease-causing

252 by the microorganism Legionella pneumophila Serogroup (Sg) 1.

253 . influenzae hpd, and S. pneumoniae lytA and serogroup-specific genes in the cap locus for N. meningi

254 each NSP4 tested had viroporin activity, but serogroup-specific viroporin phenotypes were identified.

255 , we performed deep RNA sequencing using O39 serogroup strain AM-19226 and derivatives carrying delet

256 Death was associated with uncommon O serogroup strains (P = .014) and severe disease with O7

257 A subset of non-O1/non-O139 serogroup strains of Vibrio cholerae cause disease using

258 n associated with pathogenic non-O1/non-O139 serogroup strains of Vibrio cholerae.

259 rotection is effective across L. pneumophila serogroups, suggesting that Abs specific for conserved p

260 Of these serogroups, the Crimean-Congo hemorrhagic fever virus (C

261 able to protect against four N. meningitidis serogroups, there is currently no commercial vaccine to

262 Our results indicate that the Bhanja serogroup viruses constitute a single novel species in t

263 , the public health importance of the Bhanja serogroup viruses remains unclear, due in part to the la

264 annual relative increase in the incidence of serogroup W and serogroup C between both countries.

265 national surveillance data for meningococcal serogroup W and serogroup C disease in the Netherlands a

266 other affected countries to prevent further serogroup W cases and deaths.

267 Cases due to meningococcal serogroup W cc11 (MenW:cc11) emerged in 2012-13 in the N

268 Since 2009, the incidence of meningococcal serogroup W disease has increased rapidly in the UK beca

269 Netherlands, the incidence of meningococcal serogroup W disease increased substantially in 2015-16 c

270 me multilocus sequence typing (1546 loci) on serogroup W disease isolates from both countries for sur

271 n increase in the incidence of meningococcal serogroup W disease.

272 For both the current serogroup W outbreak and the historical serogroup C outb

273 al and phylogenetic associations between the serogroup W outbreaks in the Netherlands and England, an

274 the historical similarities of meningococcal serogroup W with meningococcal serogroup C emergence, th

275 In the serogroups W and Y, these are heteropolymers of the repe

276 Southern cone was caused by serogroup B, but serogroup W135 strains have increased in recent years.

277 The IRR for non-A serogroups was higher after completion of MenAfriVac cam

278 attenuated viral vaccine candidates for this serogroup, we have generated a recombinant LACV expressi

279 Altogether, 45 different serotypes or serogroups were correctly predicted among the 196 resolv

280 All serogroups were found to display unique melting temperat

281 belong to the California encephalitis virus serogroup, which causes 70 to 100 cases of encephalitis

282 bacterial pathogen that consists of over 200 serogroups with differing pathogenic potential.

283 t among isolates belonging to the O1 and O18 serogroups within phylogenetic group B2, which are impli

284 Serogroup X N. meningitidis (NmX) dominated in both vacc

285 Serogroup Y (MenY) strains are a major cause of meningoc

286 0% (95% CI 17.3-55.0) carriage reduction for serogroup Y and 36.2% (15.6-51.7) carriage reduction for

287 w the dominating serogroup, and in 2012, the serogroup Y disease incidence was 0.46/100,000 populatio

288 jective of this study was to investigate the serogroup Y emergence by whole-genome sequencing and com

289 sease (IMD) caused by Neisseria meningitidis serogroup Y has increased in Europe, especially in Scand

290 to 2012 (n = 143), which had relatively low serogroup Y incidence, and two isolates obtained in 1999

291 In Sweden, serogroup Y is now the dominating serogroup, and in 2012

292 -genome sequencing was performed on invasive serogroup Y isolates from 1995 to 2012 in Sweden (n = 18

293 se isolates were compared to a collection of serogroup Y isolates from England, Wales, and Northern I

294 pact of a meningococcal conjugate vaccine on serogroup Y meningococcal carriage and to define the dyn

295 d to reveal additional genes associated with serogroup Y meningococcal disease, and this work would b

296 and this work would benefit from a complete serogroup Y meningococcal reference genome.

297 obtained in 1999 in the United States, where serogroup Y remains one of the major causes of IMD.

298 There were only 5 observed acquisitions of serogroup Y strains during the study; therefore, the imp

299 cal population structure of Swedish invasive serogroup Y strains to those of other countries with dif

300 serogroups B and C were equally present, and serogroup Y was frequently isolated.